UNSPSC 51332516: Bromperidol decanoate

This classification denotes an antipsychotic agent C31H41BrFNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73LG72M4LV, chemically known as decanoic acid, 4-(4-bromophenyl)-1-(4-(4-fluorophenyl)-4-oxobutyl)-4-piperidinyl ester, but more generally known as bromperidol decanoate, which bears US NIH Compound Identifier 156321. European Medicines Agency schedules Bromperidol decanoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00880MIG.

Most nations, for tariff and trade purposes, schedule bromperidol decanoate under HS 29333999 and SITC 51574. As of Q4 2014, BROMPERIDOL DECANOATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCC(=O)OC1(CCN(CC1)CCCC(=O)C2CCC(CC2)F)C3CCC(CC3)BR.

UNSPSC 51332516 Bromperidol decanoate is a Commodity code that in practice captures pharmaceutical procurement across state and local health systems, though recent state and local solicitations under this code show little direct activity in bromperidol decanoate itself. Instead, the code is being used by state agencies and counties to acquire a broader range of pharmaceuticals and medical supplies — naloxone, generic multi-source drugs, and over-the-counter products — through competitive bidding and cooperative purchasing vehicles. State health departments, county public health agencies, and multistate cooperative alliances are the primary issuing bodies, with purchasing driven by community health initiatives, pharmacy benefit optimization, and supply chain standardization across participating jurisdictions. The Seminole County procurement illustrates the operational reality: counties are buying emergency medical supplies like naloxone in volume to support opioid response and community health, while state HHS commissions are exploring direct-to-manufacturer prescription models to reduce pharmacy benefit costs and improve fulfillment efficiency.

Geographic activity centers on Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) serving multiple states including Oregon. Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS) on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026 (note: the due date field shows July 26, 2023, but the posted date is June 30, 2026, indicating a data inconsistency in the source). The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs. The Minnesota Department of Administration, administering MMCAP, issued an RFP (S1070000015802) on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to work through authorized wholesalers and certify cGMP and Drug Supply Chain Security Act compliance. These solicitations are structured as fixed-price contracts with administrative fees, quarterly or ongoing deliveries, and two-year initial terms with optional renewals.